Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Tenthoff covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Moderna, and Arrowhead Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus ...
The company’s shares closed yesterday at $2.38. Tenthoff covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Moderna, and Arrowhead Pharmaceuticals. According to TipRanks, ...
GlobalData on MSN3d
Moderna’s mRESVIA vaccine gains Health Canada approvalModerna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...
Subscribe today to gain access to every Research Intelligencer article we publish as well as the exclusive daily newsletter, ...
Moderna (MRNA) shares are getting a boost in Thursday's pre-market trading as the pharmaceutical giant reported an unexpected profit in its third quarter. The company posted $1.86 billion in revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback